VF
CBIO

Virtu Financial’s Crescent Biopharma CBIO Stock Holding History

Virtu Financial’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-363
Closed -$8K – 1682
2025
Q1 		$8K Buy
+363
New +$9.71K ﹤0.01% 1207
2024
Q4 		– Sell
-195
Closed -$3K – 1719
2024
Q3 		$3K Buy
+195
New +$4.09K ﹤0.01% 1260
2024
Q1 		– Sell
-343
Closed -$81K – 1656
2023
Q4 		$81K Buy
+343
New +$53.3K 0.01% 1071
2021
Q4 		– Sell
-541
Closed -$119K – 1886
2021
Q3 		$119K Buy
+541
New +$115K 0.01% 1087
2021
Q1 		– Sell
-128
Closed -$48K – 1767
2020
Q4 		$48K Buy
+128
New +$44.9K 0.01% 1236
2018
Q1 		– Sell
-125
Closed -$210K – 2191
2017
Q4 		$210K Buy
+125
New +$165K 0.01% 1628

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Virtu Financial's CBIO Position: Q2 2025 in Review

Virtu Financial sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 363 shares — an estimated $8K sold.

Virtu Financial first reported a position in CBIO in Q4 2017 and held it in 6 quarters. The position peaked at $210K in Q4 2017. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Virtu Financial reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Virtu Financial sold 363 Crescent Biopharma shares in Q2 2025, an estimated $8K.
  • Virtu Financial first reported a position in Crescent Biopharma in Q4 2017 and held it in 6 quarters.
  • Virtu Financial's Crescent Biopharma position peaked at $210K in Q4 2017.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.